OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE: TAK) announced that it has

Dr Reddy's ​Laboratories ‌said on ​Friday ​it signed a ⁠deal ​with ​Takeda Pharmaceutical Company ​f

Takeda Pharmaceutical Co (NYSE:TAK) released first-quarter financial results and hosted an earnings

Takeda Pharmaceutical (NYSE: TAK - Get Free Report) and Teva Pharmaceutical Industries (NYSE: TEVA -

Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare

SIG, TAK and TX made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 14th, 2026.

TX, HPQ and TAK made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 14th, 2026

Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearan

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the U.S.

MALMO, Sweden & WILMINGTON, Del.--(BUSINESS WIRE)--Trialbee, the global patient recruitment leader r

Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the New

ABVC BioPharma (NASDAQ: ABVC - Get Free Report) and Takeda Pharmaceutical (NYSE: TAK - Get Free Repo

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Weave Bio, the leader in AI-native regulatory automation for d

Nearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower price

The FDA approved Takeda's MIMRYLO to treat erythrocytosis in adults with polycythemia vera, offe

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and

The U.S. ​Food and ‌Drug Administration ​has approved a ​first-of-its-kind drug from ⁠Takeda ​Pharma

Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced that the Ja

The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). Wh

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

SBLK, TAK and STBA made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 17, 2026.

TAK, VLO, PFX, SBLK and RELY have been added to the Zacks Rank #1 (Strong Buy) List on August 17, 20

Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA

Vinod Khosla says AI is revolutionizing drug discovery, but drug testing needs to catch up with more

Takeda secured FDA approval for ORZEYFUL, a first-in-class oral orexin treatment for adults with nar

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of

ELRiSE MDS is a Phase 3, multicenter, open-label, randomized trial to compare the efficacy and safet

Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 Adj EPS guidance from $3.01 to $3.01 vs $1.57 ana

Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 GAAP EPS guidance from $0.66 to $0.66. Affirms FY

Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.48 per share which beat the analy

Takeda shares positive Phase 3 data for its oral psoriasis drug zasocitinib, showing high skin clear

New data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly se

The developer of the world’s first end-to-end AI drug has projected a big leap in half-year earnings

Ministry of Health of the Republic of Indonesia Grants Plasma Fractionation License, Enabling Takeda

Takeda and Insilico Medicine launch a strategic AI drug discovery collaboration to identify next-gen

Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major

Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primar

Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh d

Takeda's psoriasis drug zasocitinib outperformed Bristol Myers Squibb's Sotyktu in a Phase 3

Takeda ((TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-bl

If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with m

Takeda faces nearly $885 million jury verdict in AMITIZA antitrust case and plans post-trial motions

Takeda eyes growth with FDA Priority Reviews for narcolepsy and PV drugs. Get the latest on TAK'

Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.28 per share which beat the analy

TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (

FDA clears Axsome's Auvelity for Alzheimer's agitation, backed by Phase 3 data, expanding it